Solid Strategic Development Plans Eliminates the Blocking Points for Live Biotherapeutic Product

Published on: Feb 8th, 2022

A French biotech had developed a live biotherapeutic product to target obesity and metabolic disease but were hindered by blocking points in the product development process. We worked alongside the Client to identify the specific regulatory and scientific gaps in their plan. This critical information helped to form the solid foundation of their regulatory strategy and nonclinical development plan.